- Home
- MCRB vs CNTX Comparison
MCRB vs CNTX Comparison
Compare MCRB & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- CNTX
- Stock Information
- Founded
- MCRB 2010
- CNTX 2015
- Country
- MCRB United States
- CNTX United States
- Employees
- MCRB N/A
- CNTX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- CNTX Health Care
- Exchange
- MCRB Nasdaq
- CNTX Nasdaq
- Market Cap
- MCRB 142.0M
- CNTX 149.2M
- IPO Year
- MCRB 2015
- CNTX 2021
- Fundamental
- Price
- MCRB $0.85
- CNTX $1.92
- Analyst Decision
- MCRB Buy
- CNTX Strong Buy
- Analyst Count
- MCRB 4
- CNTX 3
- Target Price
- MCRB $4.17
- CNTX $6.83
- AVG Volume (30 Days)
- MCRB 5.4M
- CNTX 396.8K
- Earning Date
- MCRB 10-31-2024
- CNTX 11-07-2024
- Dividend Yield
- MCRB N/A
- CNTX N/A
- EPS Growth
- MCRB N/A
- CNTX N/A
- EPS
- MCRB N/A
- CNTX N/A
- Revenue
- MCRB $374,000.00
- CNTX N/A
- Revenue This Year
- MCRB N/A
- CNTX N/A
- Revenue Next Year
- MCRB N/A
- CNTX N/A
- P/E Ratio
- MCRB N/A
- CNTX N/A
- Revenue Growth
- MCRB N/A
- CNTX N/A
- 52 Week Low
- MCRB $0.54
- CNTX $0.77
- 52 Week High
- MCRB $2.06
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- MCRB 42.22
- CNTX 41.13
- Support Level
- MCRB $0.80
- CNTX $1.81
- Resistance Level
- MCRB $1.07
- CNTX $2.03
- Average True Range (ATR)
- MCRB 0.12
- CNTX 0.19
- MACD
- MCRB -0.02
- CNTX -0.00
- Stochastic Oscillator
- MCRB 12.26
- CNTX 24.68
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.